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The epithelial to mesenchymal transition (EMT) 
is the process characterized by the loss of epithelial 
characteristics and the acquisition of mesenchymal 
attributes by epithelial cells. EMT provides the progres-
sion of cancer cells to the metastatic phenotype and 
contributes to epithelial tumor cells to migrate, invade 
into the surrounding stroma and spread to secondary 
organs [1]. Classification of EMT into three different 
subtypes EMTs are encountered in three distinct bio-
logical settings that lead to different functional con-
sequences: 
• EMT that occurs during embryogenesis and deve-
lopment of organs;
• EMT associated with regeneration of tissue and 
organ fibrosis;
• EMT associated with tumor progression and me-
tastasis. 
A proposal to classify EMTs into three different 
biological subtypes based on the biological context 
in which they occur was discussed at a 2007 meeting 
on EMT in Poland and a subsequent meeting in March 
2008 at Cold Spring Harbor Laboratories. We have 
paid special attention to the third type of EMT, which 
includes some certain patterns such as:
• enhanced migratory capacity, invasiveness;
• elevated resistance to apoptosis; 
• greatly increased production of ECM components. 
These changes include activation of transcrip-
tion factors, expression of specific cell-surface and 
cytoskeletal proteins, production of ECM-degrading 
enzymes, and modulation of the expression of specific 
microRNAs [2, 3].
It is known that epithelial and mesenchymal cells 
have been identified on the basis of their morphology: 
typical epithelium is a sheet of cells with individual 
epithelial cells abutting each other in a uniform block. 
Regularly spaced cell-cell junctions and adhesions 
between neighboring cells hold them tightly together 
and inhibit the moment of individual cells away from the 
epithelial monolayer. On the other hand, mesenchymal 
cells usually exhibit neither regimented structure nor 
tight intracellular adhesion and these cells form struc-
tures with irregular shape. Adhesion between mesen-
chymal cells is not so strong than in epithelium and 
mesenchymal migration is mechanistically different 
from epithelial one: mesenchymal cells move individu-
ally more dynamically than epithelial cells, which move 
as a sheet in block [4]. Today there are many markers 
that characterize these types of cells at the molecular 
level. The transformation of epithelial cells to mesen-
chymal requires changes in morphology, cell adhesion 
and the ability to migrate. Standard changes occur-
ring in the process of EMT include increased expres-
sion of N-cadherin and vimentin, nuclear localization 
of β-catenin and increased production of transcription 
factors such as Snail, Slug, ZEB1, ZEB2, Twist, Twist, 
E47, which suppress the expression of E-cadherin, 
which in turn, cause an increased capacity for migra-
tion and invasion, and resistance to apoptosis.
The understanding of the processes of EMT and 
mezenchymal-epithelial transition (MET) to tumor pro-
gression and monitoring of these processes in clinical 
practice is of great importance, as well as the search 
for modifiers of these processes, as it will provide 
new targets for treatment and help to change routine 
schemes of therapy [5, 6]. 
According to our opinion, such a modifier can 
be interferon. More than a half a century ago, interfer-
ons (IFN) were identified as antiviral cytokines. Since 
that discovery, IFN have been in the forefront of basic 
and clinical cytokine research. The pleiotropic nature 
of these cytokines continues to engage a large number 
of investigators to define their actions further. Modern 
studies have demonstrated that IFN is a polypotent 
cytokine that is able to suppress proliferation of ma-
lignant cells, and sometimes is causing their direct 
lysis; it causes suppression of angiogenesis in tumor 
tissue and stimulates specific immune response and 
nonspecific antitumor resistance of an organism; IFN 
possesses antimutagenic activity, promotes apoptosis 
in tumor cells induced by different agents; it sup-
presses  motility of tumor cells and expression of on-
cogenes; IFN influences the mechanisms of tumor cell 
differentiation [7–9]. Also, it has been shown that IFN 
modifies interactions between the cells and with dif-
ferent biologic substances: antibodies, lymphokines, 
cytokines, hormones, growth factors, etc.
Earlier using the murine cells transformed with viral 
oncogenes it has been shown that IFN suppresses 
malignancy of transformed cells and this effect of IFN 
may have been related to the changes in the methyla-
tion of viral and/or cellular genes. The ability of IFN 
to reverse malignant phenotype of tumor cells is mani-
fested in a long-term action of this cytokine on human 
tumor cells in vitro [10]. 
In our study we have used the experimental model 
of prolonged exposition of tumor cells to IFN because 
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we have taken into account the clinical schedules 
of long-term courses of interferon therapy; from 
other hand, the data on IFN influence on numerous 
patterns of the cells has been reported for short-term 
exposition of the cells to IFN, after which the modified 
properties of cells were renewed. 
The ability of IFN to induce suppression of tumor 
cells malignancy is in some way related to its well 
known ability to stimulate tumor cell differentiation. 
Recently it was also shown that IFN inhibits the pro-
cesses of fibrosis in vivo [11]. The above brief descrip-
tion of the IFN activities directly points on its possible 
involvement in control of the process of EMT and 
induction of MET.
Such assumptions we’ve proposed because IFN 
also has a permanent effect on the cells in organism 
where it is an endogenous factor, which can be acti-
vated in different situations for control of homeostasis. 
In our work we have used non small cell lung cancer 
cells of А-549 line, HeLa — cervical carcinoma, K-562 — 
chronic myelogenous leukemia obtained from the Bank 
of Cell Lines from Human and Animal Tissues(Kyiv, 
Ukraine), which were cultured in complete RPMI 
1640 culture medium (Sigma, USA) supplemented with 
4 mmole/L L-glutamine, 10% fetal calf serum (Sigma, 
USA), and 40 μg/ml gentamycine. The cells were cul-
tivated in humidified 5% СО2 atmosphere at 37 °С, the 
medium was replaced each two days, and the cells were 
passaged each four days. To study the long-term effect 
of IFN, the cells were cultivated for more than 2 month 
(A-549 — for 1 year) in the presence of recombinant 
IFN-alpha-2b (BioPharma, Ukraine) at increasing con-
centrations (from 100 to 10000 U/ml). 
The expression levels of E-cadherin, N-cadherin, 
vimentin and actin (smooth-muscle actin) proteins 
were analyzed using immunocytochemical approach 
with the use of monoclonal antibodies (Dako North 
America, BioLegend, Diagnostic BioSystems).
Our previous study of growth kinetics of А-549 and 
K-562 cells and recent studies of HeLa cells that 
were cultivated with or without IFN in vitro has shown 
significant alterations of growth patterns of the cells 
exposed to IFN [12]. In particular, it has been revealed 
that along with prolongation of cell exposition period 
and elevation of IFN concentration, the period of cell 
duplication becomes longer, cells became larger and 
some of them demonstrated enhanced manifestation 
of epithelial morphology. We also have shown that pro-
longed cultivation of А-549 cells with IFN leads to dra-
matic decrease of the number and size of colonies 
of A549 cells in semisoft medium; IFN-modified tumor 
cells lost an ability to grow in serum-free culture me-
dium; also, we have revealed a decreased expression 
of EGF-R and VEGF. So, all these acquired abilities 
of IFN-modified cells indicate a significant reduction 
of their tumorigenicity.
We showed that the long-term exposition 
of A-549 adenocarcinoma cells to IFN-alpha leads 
to reliable decrease in the number of cells expressing 
vimentin and leads to strong increase in the number 
of cells, which express E-cadherin (Table). At the 
same time we revealed that the long-term exposi-
tion of A-549 cells to IFN leads to decreased number 
of N-cadherin-positive cells. It is known that E-cad-
herin is responsible for maintaining interactions of epi-
thelial cells and is frequently downregulated during 
tumor progression, while N-cadherin that is normally 
found in fibroblasts and neural cells, can be upregu-
lated during tumor progression and can increase the 
invasiveness of tumor cells [13]. We have registered 
increase of E-cadherin expression and decrease 
of N-cadherin and vimentin expression after prolonged 
treatment of HeLa and K-562 cells with IFN (Fig. 1, 2, 
see Table). From these data we can conclude that IFN 
can be involved in the control of EMT/MET programs 
of tumor cell transdifferentiation because all studied 
proteins are the markers of this process. 
So, we have shown that long-term treatment of hu-
man cancer cells by IFN-alpha leads to alterations 
in expression of epithelial and mesenchymal markers, 
which indicate inhibition of EMT program and activa-
tion of MET program. This phenomenon correlates 
with inhibition of malignant phenotype of cancer cells. 
It opens a novel direction of investigation of the IFN — 
one of the most important regulator of homeostasis 
in systemic level and genetic stability on cellular level, 
especially in a situation where almost nothing is known 
about this cytokine as a modifier of EMT. 
Our hypothesis requires further evidence. In gen-
eral, it is a good explanation of many experimental 
data and clinical effects of IFN, which are attributed 
to the other properties of this cytokine. Search in this 
way helps us find new and important target for the 
suppression of aggressive behavior of cancer cells. 
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Table. Change of some EMT protein marker expression in the IFN-treated tumor cells
№ Markers 
Cell line
A-549 HeLa K562
control, % IFN-modified, % control, % IFN-modified, % control, % IFN-modified, %
1 E-cadherin 22±1.3 63±2.6 21.4±3.1 93±4.1 negative 100
2 N-cadherin 100 46±4.1 100 54.2±4.4 negative negative
3 Vimentin 98±1.36 73±1.73 100 100 88±3.6 41.3±1.2
4 Alpha-smooth muscle actin 100 87±3.2 negative negative negative negative
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Fig. 1. Immunocytochemical analysis of expression of E-cad-
herin in HeLa (a, b) and K-562 (c, d) cells: control (a, c), IFN-
modified cells (b, d) (x1000)
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Fig. 2. Immunocytochemical analysis of expression of N-cad-
herin in HeLa (a, b) and vimentin in K-562 (c, d) cells: control (a, 
c), IFN-modified cells (b, d) (x1000)
Experimental Oncology 33, 178–181, 2011 (September) 181
5. McConkey DJ, Choi W, Marquis L, et al. Role of 
epithelial-to-mesenchymal transition (EMT) in drug sensitiv-
ity and metastasis in bladder cancer. Cancer Metastasis Rev 
2009; 28: 335–44.
6. M.Lee J, Dedhar S, Kalluri R, et al. The epithelial-
mesenchymal transition: new insights in signaling, develop-
ment, and disease. J Cell Biol 2006; 172: 973–81.
7. Biological methods for treatment of cancer. DeVita T, 
Hellman C, Rosenberg AC, eds. Moskow: Meditsina, 2002; 
920 p (In Russian).
8.  Vilcek J. My fifty years with interferon. J Interferon 
Cytokine Res 2007; 27: 535–41.
9. Vorontsova AL, Kudryavets YI. Interferon as an 
important element in optimizing the treatment of cancer 
patients. Oncologiya 2000; 2: 16–24 (In Russian).
10. Lуpez-Ocejo O, Perea SE, Bequet-Romero M, et al. 
Impaired angiogenic balance and suppression of tumorige-
nicity in HeLa cells chronically exposed to interferon-alpha. 
Biochem Biophys Res Commun 2000; 277: 410–6.
11. Takahara T, Sugiyama K, Zhang LP, et al. Cotreatment 
with interferon-alpha and-gamma reduces liver fibrosis in a 
rat model. Hepatol Res 2004; 28: 146–54.
12. Kudryavets YuI, Bezdenezhnykh NO, Lukyanova NYu, 
et al. Modifying influence of prolonged action of interferon on 
phenotypic characteristics of human lung cancer cells in vitro. 
Exp Oncol 2008; 30: 283–8.
13. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Dif-
ferential cadherin expression: potential markers for epithelial 
to mesenchymal transformation during tumor progression. J 
Mammary Gland Biol Neoplasia 2007; 12: 127–33.
Copyright © Experimental Oncology, 2011
